Efficacy of Extracorporeal Shockwave Therapy on Plantar Fasciitis in Patients With Peripheral Neuropathy
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-90
SponsorNational Taiwan University Hospital
About this trial
This study aims to evaluate the efficacy of extracorporeal shockwave therapy (ESWT) in reducing pain and improving functional outcomes for patients with neuropathy-associated plantar fasciitis.
Eligibility criteria
Qualifiers
Age 18 or older and 90 or younger.
Ability to give informed consent.
Presence of peripheral neuropathy, confirmed by clinical symptoms, nerve
conduction study, autonomic function test, quantitative sensory test, or skin biopsy.
Disqualifiers
Presence of severe systemic diseases, including severe ischemic heart disease or congestive heart failure (left ventricular ejection fraction < 30%), severe lung diseases with dyspnea, severe generalized edema, uncontrolled diabetes, and systemic infection.
Presence of severe peripheral vascular disease.
Presence of an implanted cardiac pacemaker, deep brain stimulator, or metallic implants (for example, internal fixation plates, screws, etc.) within the affected foot or ankle.
Presence of ruptured or pre-ruptured tendons in the target area. A diagnostic softtissue ultrasound of the plantar foot will be performed to assess tissue integrity if any of the following clinical red flags are identified: localized soft-tissue swelling or ecchymosis; physical examination findings indicative of a loss of continuity or tension in the plantar fascia; a history of local corticosteroid injection within the past 12 months; or a history of surgical intervention involving the affected foot.
Trial design
Treatments tested in this trial
- Extracorporeal shockwave therapy (ESWT)
Treatment groups
114 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov